This article possibly contains original research. Please improve it by verifying the claims made and adding inline citations. Statements consisting only of original research should be removed. (December 2022) (Learn how and when to remove this template message)
Immunoscintigraphy
Purposedetect cancer cells

Immunoscintigraphy is a nuclear medicine procedure used to find cancer cells in the body by injecting a radioactively labeled antibody, which binds predominantly to cancer cells and then scanning for concentrations of radioactive emissions.[1][2]

Clinical applications

Immunoscintigraphy is performed using a variety of radiopharmaceuticals, for a large range of purposes. Colorectal cancer is one of the most studied areas, with indium-111 or technetium-99m labelled epitopes of the carcinoembryonic antigen.[3] The antibody capromab pendetide reacts with prostate membrane specific antigen (PMSA) and can be labelled with 111In.[4]

See also

References

  1. ^ "Imaging Techniques for the Diagnosis of Ovarian Cancers: Immunoscintigraphy". 21 December 2004.
  2. ^ "Immunoscintigraphy". NCI Dictionary of Cancer Terms. National Cancer Institute. Retrieved 1 June 2017.
  3. ^ Matzku, Siegfried; Stahel, Rolf A (1999). Antibodies in Diagnosis and Therapy. CRC Press. p. 143. ISBN 9789057023101.
  4. ^ Fass, Leonard (August 2008). "Imaging and cancer: A review". Molecular Oncology. 2 (2): 115–152. doi:10.1016/j.molonc.2008.04.001. PMC 5527766. PMID 19383333.


Categories